Ubs Group Ag Ocular Therapeutix, Inc Transaction History

Ubs Group Ag

$555 Billion
Q2 2025

A detailed history of Ubs Group Ag transactions in Ocular Therapeutix, Inc stock. As of the latest transaction made, Ubs Group Ag holds 1,965,151 shares of OCUL stock, worth $23.2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,965,151

Previous 1,334,939 47.21%

Holding current value

$23.2 Million

Previous $9.79 Million 86.37%

% of portfolio

0.0%

Previous 0.0%

32 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$6.02 - $9.46 $3.79 Million - $5.96 Million	630,212 Added 47.21%	1,965,151 $18.2 Million
Q1 2025 May 13, 2025	BUY	$5.93 - $9.08 $2.72 Million - $4.16 Million	458,393 Added 52.3%	1,334,939 $9.79 Million
Q4 2024 Feb 14, 2025	BUY	$8.33 - $11.47 $1.6 Million - $2.2 Million	191,770 Added 28.0%	876,546 $7.49 Million
Q3 2024 Nov 14, 2024	SELL	$6.45 - $9.23 $412,522 - $590,323	-63,957 Reduced 8.54%	684,776 $5.96 Million
Q2 2024 Aug 13, 2024	BUY	$4.2 - $8.69 $1.11 Million - $2.3 Million	265,227 Added 54.85%	748,733 $5.12 Million
Q1 2024 May 13, 2024	BUY	$3.85 - $10.93 $1.51 Million - $4.29 Million	392,673 Added 432.3%	483,506 $4.4 Million
Q4 2023 Feb 09, 2024	BUY	$2.08 - $4.52 $77,498 - $168,410	37,259 Added 69.55%	90,833 $405,000
Q3 2023 Nov 09, 2023	SELL	$3.14 - $5.04 $239,823 - $384,940	-76,377 Reduced 58.77%	53,574 $168,000
Q2 2023 Aug 11, 2023	BUY	$4.6 - $7.64 $591,900 - $983,069	128,674 Added 10076.27%	129,951 $670,000
Q4 2022 Feb 08, 2023	BUY	$2.61 - $4.41 $722 - $1,221	277 Added 27.7%	1,277 $3,000
Q3 2022 Nov 10, 2022	SELL	$4.09 - $6.5 $1.4 Million - $2.22 Million	-341,228 Reduced 99.71%	1,000 $4,000
Q2 2022 Aug 10, 2022	BUY	$3.01 - $5.22 $925,105 - $1.6 Million	307,344 Added 881.05%	342,228 $1.38 Million
Q1 2022 May 16, 2022	SELL	$4.83 - $7.35 $289,828 - $441,044	-60,006 Reduced 63.24%	34,884 $173,000
Q4 2021 Feb 14, 2022	SELL	$6.16 - $12.07 $1.43 Million - $2.8 Million	-231,738 Reduced 70.95%	94,890 $661,000
Q3 2021 Nov 15, 2021	SELL	$9.7 - $14.34 $2.5 Million - $3.7 Million	-258,165 Reduced 44.15%	326,628 $3.27 Million
Q2 2021 Aug 13, 2021	BUY	$13.43 - $19.16 $455,666 - $650,079	33,929 Added 6.16%	584,793 $8.29 Million
Q1 2021 May 12, 2021	SELL	$15.82 - $22.11 $1.1 Million - $1.53 Million	-69,232 Reduced 11.16%	550,864 $9.04 Million
Q4 2020 Feb 11, 2021	BUY	$7.91 - $22.95 $3.82 Million - $11.1 Million	483,347 Added 353.46%	620,096 $12.8 Million
Q3 2020 Nov 12, 2020	SELL	$7.36 - $9.87 $204,953 - $274,849	-27,847 Reduced 16.92%	136,749 $1.04 Million
Q2 2020 Jul 31, 2020	BUY	$4.67 - $8.95 $615,067 - $1.18 Million	131,706 Added 400.44%	164,596 $1.37 Million
Q1 2020 May 01, 2020	SELL	$3.95 - $7.4 $78,229 - $146,557	-19,805 Reduced 37.58%	32,890 $163,000
Q4 2019 Feb 14, 2020	BUY	$2.57 - $4.73 $68,906 - $126,820	26,812 Added 103.59%	52,695 $208,000
Q3 2019 Nov 14, 2019	BUY	$3.04 - $5.32 $77,164 - $135,037	25,383 Added 5076.6%	25,883 $79,000
Q1 2019 May 14, 2019	SELL	$3.51 - $4.77 $4,994 - $6,787	-1,423 Reduced 74.0%	500 $2,000
Q4 2018 Feb 14, 2019	SELL	$3.87 - $7.11 $52,682 - $96,788	-13,613 Reduced 87.62%	1,923 $8,000
Q3 2018 Nov 14, 2018	SELL	$5.42 - $6.99 $85,278 - $109,980	-15,734 Reduced 50.32%	15,536 $107,000
Q2 2018 Aug 14, 2018	BUY	$5.99 - $8.17 $142,382 - $194,200	23,770 Added 316.93%	31,270 $211,000
Q1 2018 May 15, 2018	BUY	$4.66 - $7.08 $7,260 - $11,030	1,558 Added 26.22%	7,500 $49,000
Q4 2017 Feb 14, 2018	SELL	$3.73 - $6.37 $8,366 - $14,287	-2,243 Reduced 27.4%	5,942 $26,000
Q3 2017 Nov 14, 2017	BUY	$5.28 - $6.88 $16,024 - $20,880	3,035 Added 58.93%	8,185 $51,000
Q2 2017 Aug 14, 2017	SELL	N/A	-2,406 Reduced 31.84%	5,150 $48,000
Q1 2017 Nov 14, 2017	BUY	N/A	7,556	7,556 $70,000

Others Institutions Holding OCUL

# of Institutions

204

Shares Held

137M

Call Options Held

743K

Put Options Held

321K

View Full List

About OCULAR THERAPEUTIX, INC

Ticker OCUL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,966,896
Market Cap $910M
Description
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cat...

More about OCUL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account